Gland Pharma announced strong Q3 FY26 results, highlighted by a 22% year-on-year revenue growth and a 37% increase in adjusted PAT. The company’s performance was boosted by double-digit growth in the US and Europe, alongside margin improvements. Cenexi’s breakeven also contributed to the positive results. The company remains optimistic about sustaining growth through new product launches and operational efficiencies.
Financial Performance Highlights
Gland Pharma reported revenue from operations of ₹16,954 million for Q3 FY26, a 22% increase compared to ₹13,841 million in Q3 FY25. Nine-month revenue increased by 12%. Adjusted EBITDA for Q3 FY26 stood at ₹4,490 million, a 25% increase year-on-year, resulting in an adjusted EBITDA margin of 26%. Adjusted PAT increased by 37% to ₹2,797 million.
Segment Performance
In Q3 FY26, the US market contributed ₹8,685 million in revenue, a 19% increase year-on-year. Europe showed strong growth, with revenue increasing by 54% to ₹4,071 million. Revenue from India increased by 32% to ₹744 million.
Key Growth Drivers
The company’s strong performance in Q3 FY26 was driven by consistent execution and growth across key markets, particularly in the US and Europe. Improved margins also contributed to the positive results. Additionally, Cenexi’s breakeven and strong revenue traction in the base business supported the consolidated performance.
R&D and Product Development
Research and development expenses for Q3 FY26 totaled ₹650 million, representing 5.4% of revenue. The company launched nine new molecules in the US during the quarter. Nine ANDA filings were submitted, and four ANDAs were approved. Total ANDA filings in the US now stand at 384.
Cenexi Financials
Cenexi reported revenue of €50 million for the quarter, compared to €41 million in the prior year, with a gross profit of €39 million. EBITDA stood at €1.4 million.
Source: BSE
